The United Laboratories International Holdings Limited (03933.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.3x

Market Cap

HKD 25.03B

MomentumView details →

1D Return

−0.65%

YTD Return

−27.91%

RSI (14)

38.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.3x

Market Cap

HKD 25.03B

RSI (14)

38.1

MomentumView details →

1D Return

−0.65%

YTD Return

−27.91%

ProfitabilityView details →

Gross Margin

39.97%

Net Margin

13.90%

EBITDA Margin

19.84%

ROE (TTM)

20.90%

ROA (TTM)

11.20%

Asset Turnover

0.82x

GrowthView details →

Revenue YoY

−4.41%

EPS YoY

−30.81%

FCF YoY

−72.77%

Revenue CAGR 3Y

+5.24%

EPS CAGR 3Y

+8.46%

EBITDA YoY

−27.88%

EarningsView details →

EPS (Actual)

HKD 0.20

EPS Surprise

35.53%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

35.53%

Rev Surprise

10.77%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

2.05x

Quick Ratio

1.77x

Div Yield

5.67%

Div Rate

HKD 0.47

Div Growth 1Y

−47.47%

Financials snapshotView financials →

Revenue (TTM)

25.87B

Net Income (TTM)

3.60B

Op. CF (TTM)

—

Next earningsMar 30, 2027 →

Latest newsMore news →

United Laboratories International Holdings Limited reported interim results for the six months ended June 2026, with revenue of RMB 6.166 billion, down 18% year-on-year, and net profit of RMB 348 million, down 81.6% year-on-year.4d ago

China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.8d ago

Similar companies

华海药业600521.SH China Medical System Holdings Limited00867.HK Aprogen Biologics Inc.003060.KS 达仁堂600329.SH China Resources Pharmaceutical Group Limited03320.HK 济川药业600566.SH Find similar companies →

Latest newsMore news →

United Laboratories International Holdings Limited reported interim results for the six months ended June 2026, with revenue of RMB 6.166 billion, down 18% year-on-year, and net profit of RMB 348 million, down 81.6% year-on-year.4d ago China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.8d ago